Janux Therapeutics Inc shares fell 50.69%, hitting a 52-week low. This decline occurred despite the company reporting positive interim data for its drug JANX007 in a Phase 1 trial for metastatic castration-resistant prostate cancer (mCRPC).
The interim results indicated a 30% partial response rate among heavily pre-treated patients, showcasing significant anti-tumor activity. Additionally, the safety profile was deemed manageable, with most adverse effects being mild. However, the market reacted negatively, leading to a sharp decline in share price.
Investors may be concerned about the broader market sentiment, as Janux's shares dropped significantly despite the positive clinical data. This reaction highlights the volatility in biotech stocks, where positive news can sometimes be overshadowed by market dynamics.
Wall Street analysts forecast JANX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JANX is 55.25 USD with a low forecast of 25.00 USD and a high forecast of 150.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Analyst Rating
Wall Street analysts forecast JANX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JANX is 55.25 USD with a low forecast of 25.00 USD and a high forecast of 150.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Buy
1 Hold
0 Sell
Strong Buy
Current: 13.950
Low
25.00
Averages
55.25
High
150.00
Current: 13.950
Low
25.00
Averages
55.25
High
150.00
Clear Street
Buy -> Hold
downgrade
$32 -> $12
2026-01-20
Reason
Clear Street
Price Target
$32 -> $12
AI Analysis
2026-01-20
downgrade
Buy -> Hold
Reason
Clear Street downgraded Janux Therapeutics to Hold from Buy with a price target of $12, down from $32. The firm says the the absence of clear durability signals from JANX007 and the lack of incremental data from JANX008 "introduce material platform risk." Janux faces rising competitive momentum and an undefined path for JANX007, which elevates its execution risk, the analyst tells investors in a research note.
Piper Sandler
Kelsey Goodwin
Overweight
downgrade
$42 -> $30
2026-01-16
Reason
Piper Sandler
Kelsey Goodwin
Price Target
$42 -> $30
2026-01-16
downgrade
Overweight
Reason
Piper Sandler analyst Kelsey Goodwin lowered the firm's price target on Janux Therapeutics to $30 from $42 and keeps an Overweight rating on the shares. Following a flurry of updates from companies across its coverage, the firm updating its 2026 Catalyst Tracker, as well as several models and price targets.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for JANX
Unlock Now
BofA
Buy
downgrade
$49 -> $35
2026-01-06
Reason
BofA
Price Target
$49 -> $35
2026-01-06
downgrade
Buy
Reason
BofA lowered the firm's price target on Janux Therapeutics to $35 from $49 and keeps a Buy rating on the shares. The firm is updating its price targets for U.S Biopharmaceuticals under its coverage, the analyst tells investors. Over the past few months, several key items "have fallen into place," including positive data catalysts being rewarded; large-cap biopharma spending cash on M&A and in-licensing; growing backlog of companies on the private side; improving access to capital; and limited impact from drug price regulation, BofA says. The firm believes biotech is back, but the biggest concern is whether this will last.
Barclays
Overweight
downgrade
$48 -> $29
2025-12-17
Reason
Barclays
Price Target
$48 -> $29
2025-12-17
downgrade
Overweight
Reason
Barclays lowered the firm's price target on Janux Therapeutics to $29 from $48 and keeps an Overweight rating on the shares. The firm adjusted price targets in the biotechnology space as part of its 2026 outlook.
About JANX
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidates include JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr) designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
